The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40

State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46

Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21

Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev (2012) 1.18

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol (2013) 1.09

Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther (2013) 1.08

Iron deprivation in cancer--potential therapeutic implications. Nutrients (2013) 0.98

Non-invasive in vivo imaging of near infrared-labeled transferrin in breast cancer cells and tumors using fluorescence lifetime FRET. PLoS One (2013) 0.96

Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol (2014) 0.96

A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano (2014) 0.95

Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem (2014) 0.93

Phytoagents for cancer management: regulation of nucleic acid oxidation, ROS, and related mechanisms. Oxid Med Cell Longev (2013) 0.92

Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell (2014) 0.91

The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther (2013) 0.89

Barriers to drug delivery in solid tumors. Tissue Barriers (2014) 0.89

The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm (2014) 0.87

Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants. Oncotarget (2016) 0.87

How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine (2013) 0.87

Transferrin-mediated cellular iron delivery. Curr Top Membr (2012) 0.86

Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes. Mol Ther (2015) 0.86

Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Mol Cell Proteomics (2013) 0.85

Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics. Expert Opin Drug Deliv (2014) 0.84

Polymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug delivery. J Control Release (2015) 0.84

Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro (2012) 0.84

VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis (2013) 0.84

Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin. Adv Drug Deliv Rev (2012) 0.84

TfR1 interacts with the IKK complex and is involved in IKK-NF-κB signalling. Biochem J (2013) 0.83

In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials (2013) 0.83

Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends Biochem Sci (2015) 0.83

Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release (2016) 0.82

MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain. ACS Nano (2015) 0.82

Automated selection of regions of interest for intensity-based FRET analysis of transferrin endocytic trafficking in normal vs. cancer cells. Methods (2013) 0.82

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82

Application of liposomes in drug development--focus on gastroenterological targets. Int J Nanomedicine (2013) 0.81

Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine (2015) 0.81

Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. J Control Release (2015) 0.81

Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnology (2016) 0.80

Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog (2013) 0.80

Self-assembled IR780-loaded transferrin nanoparticles as an imaging, targeting and PDT/PTT agent for cancer therapy. Sci Rep (2016) 0.80

Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech (2014) 0.80

miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) (2015) 0.80

Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. Pharmaceutics (2013) 0.80

Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res (2014) 0.79

PEG-b-AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting. J Mater Chem B Mater Biol Med (2015) 0.78

Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71. Int J Endocrinol (2014) 0.78

Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. Metallomics (2014) 0.78

A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. Nucleic Acid Ther (2016) 0.78

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Sci Rep (2016) 0.77

Iron in multiple myeloma. Crit Rev Oncog (2013) 0.77

Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLoS One (2015) 0.77

Transferrin: Endocytosis and Cell Signaling in Parasitic Protozoa. Biomed Res Int (2015) 0.76

Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med (2014) 0.76

Plasmonic nanodiamonds: targeted core-shell type nanoparticles for cancer cell thermoablation. Adv Healthc Mater (2014) 0.76

NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology (2016) 0.76

Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells. Onco Targets Ther (2016) 0.76

Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. Eur J Pharm Biopharm (2016) 0.76

Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects. PLoS One (2012) 0.75

Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase. PLoS One (2016) 0.75

Functionalized nano-graphene oxide particles for targeted fluorescence imaging and photothermy of glioma U251 cells. Int J Clin Exp Med (2015) 0.75

A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther (2016) 0.75

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther (2016) 0.75

Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials (Basel) (2015) 0.75

Evaluation of Nonferrous Metals as Potential In Vivo Tracers of Transferrin-Based Therapeutics. J Am Soc Mass Spectrom (2015) 0.75

Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. J Immunother (2015) 0.75

Endocytosis of a functionally enhanced GFP-tagged transferrin receptor in CHO cells. PLoS One (2015) 0.75

Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol (2015) 0.75

Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism. PLoS One (2017) 0.75

Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. Top Curr Chem (J) (2017) 0.75

Iron depletion strategy for targeted cancer therapy: utilizing the dual roles of neutrophil gelatinase-associated lipocalin protein. J Mol Model (2016) 0.75

Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Cancer Ther (2017) 0.75

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer. Sci Rep (2017) 0.75

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09

Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05

Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release (2001) 4.81

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials (2000) 4.42

Micellar nanocontainers distribute to defined cytoplasmic organelles. Science (2003) 4.37

Nanomedicine: current status and future prospects. FASEB J (2005) 4.28

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81

Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69

Structure of the human transferrin receptor-transferrin complex. Cell (2004) 3.64

The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm (2009) 3.49

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09

The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol (2006) 3.08

PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther (1999) 2.90

Cyclodextrins and their pharmaceutical applications. Int J Pharm (2006) 2.89

The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem (1994) 2.84

Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell (1998) 2.80

Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release (2005) 2.79

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76

Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci U S A (1990) 2.64

A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A (2006) 2.55

Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol (1981) 2.30

Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction. Nat Biotechnol (1999) 2.22

Nanoparticles for drug delivery in cancer treatment. Urol Oncol (2008) 2.21

Cyclodextrin rotaxanes and polyrotaxanes. Chem Rev (2006) 2.19

Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm (1999) 2.18

Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15

Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev (2004) 2.13

Dendrimers in drug research. Chem Soc Rev (2003) 2.09

Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine (2006) 2.07

Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc Natl Acad Sci U S A (2010) 2.05

Dendrimers in Supramolecular Chemistry: From Molecular Recognition to Self-Assembly. Chem Rev (1997) 2.05

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci (2009) 1.98

The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther (1997) 1.96

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94

Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci U S A (1992) 1.87

Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci U S A (1990) 1.79

The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol (2000) 1.72

Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature (1981) 1.72

Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A (1992) 1.72

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem (2007) 1.71

Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (1983) 1.66

The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc (2010) 1.63

Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev (2008) 1.63

Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer (2004) 1.60

Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther (2002) 1.57

Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm (2005) 1.55

Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release (2009) 1.53

Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery. Bioconjug Chem (2006) 1.51

Parvoviral host range and cell entry mechanisms. Adv Virus Res (2007) 1.49

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol (2003) 1.46

Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release (2006) 1.45

Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther (1999) 1.45

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol (1996) 1.43

A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm (2003) 1.42

Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther (2004) 1.40

Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res (2001) 1.38

Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 1.37

Sorting and recycling of cell surface receptors and endocytosed ligands: the asialoglycoprotein and transferrin receptors. J Cell Biochem (1983) 1.37

Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem (2003) 1.35

Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) (2008) 1.33

Designing dendrimers for drug delivery. Pharm Sci Technolo Today (1999) 1.33

Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug Chem (2003) 1.31

A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm (2006) 1.30

Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci (2007) 1.27

Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther (2002) 1.25

Cell entry by human pathogenic arenaviruses. Cell Microbiol (2007) 1.25

Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res (1990) 1.24

Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) (2010) 1.24

Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact (2007) 1.22

Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today (2010) 1.22

Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer (2002) 1.22

Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med (2001) 1.21

DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety. Bioconjug Chem (1992) 1.21

Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1989) 1.19

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A (2002) 1.19

Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release (2001) 1.18

Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm (2007) 1.18

Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm (2009) 1.18

Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm (2007) 1.18

Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther (2005) 1.16

Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis (2006) 1.15

Liposomes as delivery systems for antibiotics. Int J Pharm (2009) 1.15

Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm Res (2010) 1.13

A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther (2007) 1.13

Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release (2007) 1.13

Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res (1985) 1.12

Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci (2009) 1.11

Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjug Chem (1999) 1.11

Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm (2006) 1.10

Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target (1999) 1.09

Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08

Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. Science (1984) 1.06

Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther (2002) 1.06

Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther (1997) 1.06

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05

Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med (2000) 1.05

A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells. J Biol Chem (1984) 1.04

Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target (2009) 1.04

The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol (2006) 3.08

C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20

The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol (2006) 2.18

Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc Natl Acad Sci U S A (2010) 2.05

[Use of sirolimus-eluting stents in complex lesions: clinical and angiographic follow-up]. Rev Esp Cardiol (2004) 1.60

Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors. Neurosurg Focus (2014) 1.59

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care (2009) 1.57

Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery. Bioconjug Chem (2006) 1.51

[Association of age, inflammatory markers and subclinical atherosclerosis in subjects free from cardiovascular disease]. Med Clin (Barc) (2008) 1.40

Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res (2009) 1.37

Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev (2013) 1.33

Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. Proc Natl Acad Sci U S A (2009) 1.26

Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care (2011) 1.23

Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact (2007) 1.22

Targeting aurora kinases as therapy in multiple myeloma. Blood (2007) 1.19

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A (2002) 1.19

Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis (2006) 1.15

Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13

Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm Res (2010) 1.13

Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release (2007) 1.13

Nutrients dynamics in the main river basins of the centre-southern region of Chile. J Hazard Mater (2009) 1.13

Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci (2005) 1.12

Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res (2005) 1.12

Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy. FEBS Lett (2005) 1.08

Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. Int J Neuropsychopharmacol (2012) 1.06

Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther (2003) 1.06

The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Crit Care (2013) 1.05

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05

Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) (2008) 1.04

Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid). Int J Mol Sci (2012) 1.02

Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther (2007) 1.00

A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med (2009) 1.00

Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab (2013) 1.00

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99

Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release (2007) 0.99

New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev (2009) 0.97

Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis (2003) 0.95

Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage (2010) 0.95

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One (2012) 0.95

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine (2003) 0.94

An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses. J Virol (2012) 0.94

The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer (2011) 0.93

New functional degradable and bio-compatible nanoparticles based on poly(malic acid) derivatives for site-specific anti-cancer drug delivery. Int J Pharm (2011) 0.91

The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery. Biomaterials (2011) 0.89

Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med (2005) 0.89

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res (2014) 0.89

Adenovirus-driven overexpression of proteinases in organ-cultured normal human corneas leads to diabetic-like changes. Brain Res Bull (2009) 0.88

Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation. Arterioscler Thromb Vasc Biol (2009) 0.88

A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng (2004) 0.88

Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci (2007) 0.88

Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. Neuropsychopharmacology (2013) 0.88

Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces (2010) 0.88

Nanoconjugate Platforms Development Based in Poly(β,L-Malic Acid) Methyl Esters for Tumor Drug Delivery. J Nanotechnol (2010) 0.87

Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release (2009) 0.87

Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One (2010) 0.86

Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol (2012) 0.86

Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma (2011) 0.86

Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther (2005) 0.86

An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother (2011) 0.86

Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release (2013) 0.85

Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol (2008) 0.85

Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother (2011) 0.85

Effect of lutein and antioxidant supplementation on VEGF expression, MMP-2 activity, and ultrastructural alterations in apolipoprotein E-deficient mouse. Oxid Med Cell Longev (2013) 0.84

Heavy metals in northern Chilean rivers: spatial variation and temporal trends. J Hazard Mater (2010) 0.84

Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro (2012) 0.84

Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J Immunol Methods (2011) 0.84

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer (2013) 0.84